CN103816169B - The application of acteoside in preparation treatment of vascular anti-dementia agent - Google Patents
The application of acteoside in preparation treatment of vascular anti-dementia agent Download PDFInfo
- Publication number
- CN103816169B CN103816169B CN201410076061.6A CN201410076061A CN103816169B CN 103816169 B CN103816169 B CN 103816169B CN 201410076061 A CN201410076061 A CN 201410076061A CN 103816169 B CN103816169 B CN 103816169B
- Authority
- CN
- China
- Prior art keywords
- acteoside
- mice
- group
- cell
- preparation treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
<b> the present invention relates to the applied technical field of acteoside, is the application of a kind of acteoside in preparation treatment of vascular anti-dementia agent; Beneficial effect of the present invention: acteoside repeatedly presss from both sides bilateral common carotid arteries and closes the logical learning memory disorder caused again and have certain protective effect; Can neurological deficit be alleviated, reduce Brain stem injury and alleviate degree of cerebral edema, thus inhibited apoptosis, the damage that final protection Focal Cerebral Ischemia Reperfusion causes; Acteoside causes cell hypoxic-ischemic to have certain protection and therapeutical effect to Hypoxia-hypoglycemia simultaneously.</b>
Description
Technical field
the present invention relates to the applied technical field of acteoside, is the application of a kind of acteoside in preparation treatment of vascular anti-dementia agent.
Background technology
vascular dementia (VascularDementia, VD) be the acquired intelligence damage syndrome causing brain tissue damage by a series of cerebrovascular factor (ischemia or hemorrhage and acute and chronic Hypoxic cerebrovascular) and cause, based on memory, Cognitive, can with language, visual space technical ability and personality disorder.Vascular dementia is a kind of commonly encountered diseases of serious puzzlement life of elderly person Quality advance, and its morbidity increases with the age and increases.VD sickness rate is higher, and in senile dementia, morbidity is only second to Alzheimer and accounts for all dull-witted 1/4 to 1/3, is considered to cause dull-witted second reason.The cerebrovascular patient of about 25% is with disturbance of intelligence in various degree.Relative to the dementia of other types, vascular dementia prognosis is better, treatment has a extensive future, and can prevent to a certain extent, along with countries in the world pace of population aging accelerates, its patient will roll up, a serious society and domestic problem are become, therefore, VD has become global emphasis public health problem, more and more causes the attention of people.Epidemiological study shows, with the age, straight line rises the sickness rate of VD, and has very big-difference between country.After adjustment age and sex, old people's annual morbidity of over-65s is 1.2% to 4.2%, and its sickness rate has more homology than prevalence, estimates that more than the 70 years old annual number of patients of old people is 6 to 12 example/1000 people.Average course of disease 5 years, and survivor is lower than general population and AD patient.The prevalence of China VD is about 1.1% to 3.0%, and annual morbidity is between 5 to 9 (example)/1000 people.Visible China is not low the area of VD, and the VD high prevalence that China faces and sickness rate bring a lot of society and economic problems, and this has to cause our attention.
acteoside is phenethyl alcohol glycosides reactive compound, exist in multiple section, platymiscium, can antibacterial, antiinflammatory, antiviral, antioxidation, immunomodulating, heart tonifying, also there is hypermnesis, anti-apoptotic, slow down aging, promote neurological functional recovery and suppress elastin laminin enzyme activity, platelet aggregation and suppress the pharmacological actions such as Endothelin increase, there is the activity of potential control cerebrovascular relevant disease.But up to now, there are no the relevant report of acteoside treatment of vascular dementia.
Summary of the invention
the invention provides the application of a kind of acteoside in preparation treatment of vascular anti-dementia agent, overcome the deficiency of above-mentioned prior art, it effectively can solve the problem that the application of acteoside in preparation treatment of vascular anti-dementia agent does not also have relevant report.
technical scheme of the present invention is realized by following measures: the application of a kind of acteoside in preparation treatment of vascular anti-dementia agent.
here is the further optimization and/or improvements to foregoing invention technical scheme:
the dosage form of above-mentioned acteoside is the one in tablet, pill, granule, capsule, suspension, solution, syrup, injection, cream, ointment, gel, spray, chewing agent and patch.
above-mentioned acteoside with the mass percentage of dry product weighing scale acteoside for 41% to 99.9%.
beneficial effect of the present invention: acteoside repeatedly presss from both sides bilateral common carotid arteries and closes the logical learning memory disorder caused again and have certain protective effect; Can neurological deficit be alleviated, reduce Brain stem injury and alleviate degree of cerebral edema, thus inhibited apoptosis, the damage that final protection Focal Cerebral Ischemia Reperfusion causes; Acteoside causes cell hypoxic-ischemic to have certain protection and therapeutical effect to Hypoxia-hypoglycemia simultaneously.
Accompanying drawing explanation
accompanying drawing 1 is the structural formula of acteoside.
accompanying drawing 2 is the influence curve figure that acteoside is expressed apoptosis-related genes bc1-2, caspase-3.
Detailed description of the invention
the present invention by the restriction of following embodiment, can not determine concrete embodiment according to technical scheme of the present invention and practical situation.
embodiment 1, the application of this acteoside in preparation treatment of vascular anti-dementia agent.
embodiment 2, as the optimization of above-described embodiment, in embodiment 2, the dosage form of acteoside is the one in tablet, pill, granule, capsule, suspension, solution, syrup, injection, cream, ointment, gel, spray, chewing agent and patch.Acteoside according to clinical needs, can add corresponding pharmaceutical carrier, exists with dosage forms such as tablet, pill, granule, capsule, suspension, solution, syrup, injection, cream, ointment, gel, spray, chewing agent or patches; Oral or parenteral mode medication can be adopted.
embodiment 3, as the optimization of above-described embodiment, in embodiment 3 acteoside with the mass percentage of dry product weighing scale acteoside for 41% to 99.9%.
in the present invention, acteoside can be obtained by synthesis, also can prepare from plant; The structural formula of acteoside as shown in Figure 1.
the checking of the application of acteoside of the present invention in preparation treatment of vascular anti-dementia agent is as follows:
one. acteoside improves cerebral hypoxia ischemia mouse model ability of learning and memory
1 experiment purpose
bilateral common carotid arteries repeatedly presss from both sides to close again and logical can cause acute cerebral ischemia and anoxia-induced apoptosis, causes hypofunction after neuron hypoxic-ischemic, comprises learning and memory function and reduce.This experiment is intended to observe acteoside and bilateral common carotid arteries is pressed from both sides repeatedly to the impact of closing again logical mouse model ability of learning and memory.
experimental technique
2.1 modelings and medication
kunming mice, weight 20 ± 2g, experiment divides 6 groups, often organizes 12: (1) normal group, (2) model group, (3) the acteoside administration group of 0.5mg/kg, (4) the acteoside administration group of 5mg/kg, (5) the acteoside administration group of 50mg/kg, (6) the acteoside administration group of 500mg/kg, the metering such as normal group and model group continuous gavage normal saline 7d, each acteoside administration group continuous gavage acteoside 7d, except normal group, all the other experimental mice, 1h after last administration, with the chloral hydrate intraperitoneal injection of anesthesia that mass percent is 4%, percent by volume is the ethanol throat skin degerming of 75%, neck median incision, be separated bilateral common carotid arteries, repeatedly press from both sides with arteriole folder and close bilateral common carotid arteries, folder closes logical that (folder closes 2 times, each 15min, centre is logical 10min again), model group and the postoperative 7d of each acteoside administration group start to carry out Morris water maze and the test of mice diving tower together with normal group, detect its ability of learning and memory.
mice diving tower is tested
ability of learning and memory is tested: by normal group, the alternating current of 36V is passed to after mice in postoperative model group and each acteoside administration group is placed on case endoadaptation 3min, when mice jumps onto insulated platform in order to hide when electric shock stimulates, start timing, record jumps off the time that platform gets shocked to mice from timing, as mice (Stepdownlatency incubation period, SDL), SDL is greater than 300s, then press 300s record, record mice in 5min simultaneously and jump off the number of times (i.e. errors number) that platform gets shocked, in this, as school grade, 1 time is repeated again after 24h, survey its memory retention.
water maze is tested
measure mice space identity ability with reference to Morris water maze laboratory method, be divided into orientation navigation and space exploration two parts.Laboratory temperature remains on 23 DEG C to 25 DEG C, adds prepared Chinese ink in water maze, and the water surface exceeds security platform 1cm, and water temperature remains on 20 DEG C to 24 DEG C, obviously can not see security platform in water.In experimentation, the putting position of indoor all objects is fixed, in order to avoid produce interference to mice.During experiment, position of platform immobilizes, and is placed in the second quadrant central authorities.Select as place of entry in the pool wall of third and fourth quadrant, each group of mice after being tested by diving tower during experiment puts into water gently towards pool wall, avoids to be immersed in the water with by mouse head.Experiment lasts 6d, and train 2 every day, mice enters water towards pool wall, and each place of entry is not identical, record mice Zi entering the time required when water climbs up platform to extremity after finding platform, as incubation period.Swimming track simultaneously after record mice enters water, using this as when analyzing mice search target adopt the foundation of which kind of strategy.Search strategy is divided into 4 classes: (1) marginal mode, mice moves along pool edge, without finding motivation; (2) random mode, without specific direction during mice search; (3) tend to formula, mice oneself remember the Position Approximate of platform, turning before discovery platform is less than 4 times; (4) orthoscopic, mice clearly remembers the position of platform, and directly trip is to platform.
orientation navigation experiment is 5d altogether, continuous repetition training twice every day.Mice is placed on 15s that platform stands, then from different quadrant, mice is put into pond, the 1st time mice is put into the fixing starting point of the second quadrant, mice is put into the fixing starting point of third quadrant, makes its free swimming, find the platform be hidden in water for the 2nd time.If mice is not found the platform in pond or fails to climb up platform after entering water in 90s, mice can be positioned over 15s that platform stands, then mice be lifted down from platform, after rest 2h, then train next time.Get every day twice incubation period meansigma methods as learning and memory achievement on the same day.
be 6d after orientation navigation experiment, start space search experiment, survey 1d, 2 times/d.1st time mice is inserted water from the starting point of third quadrant, the incubation period of record mice in 90s and the search strategy of appearing on the stage.Remove platform 2nd time, mice is inserted water from the starting point of fourth quadrant, the record number of times of mice spanning platform region in 90s and search strategy, and mice is in search time of original platform place quadrant and detection range (accounting for the percentage correction detection range of total distance to eliminate the difference of every mice swimming rate in the swimming distance of original platform place quadrant with mice).
the detection of acetylcholinesterase (AChE) vigor, malonaldehyde (MDA) content, superoxide dismutase (SOD) vigor and total antioxidant capacity (T-ACO) in serum
after the test of mice Morris water maze terminates, adopt eye socket Blood collection, after getting blood, room temperature leaves standstill 2h, with the centrifugal 10min of 3500r/min, gets upper serum, detects AChE vigor, MDA content, SOD vigor and T-ACO ability.
the detection of ChAT vigor, MDA content, SOD vigor and T-AOC ability in cerebral tissue
after mice blood sampling, sacrificed by decapitation immediately, gets cerebral tissue, isolates brain, weigh, add pre-cold saline, make the brain tissue homogenate that mass percent is 10%, with the centrifugal 10min of 3500r/min, get supernatant, detect AChE vigor, MDA content, SOD vigor and T-AOC ability.
statistical procedures
experimental result data all represents with mean ± standard deviation, adopts significance between one factor analysis of variance group to compare, compares employing between sample average
tinspection,
p< 0.05 represents that difference has statistical significance.
result
3.1 acteosides are to the average influence of mice diving tower achievement
the average influence of acteoside to mice diving tower achievement is shown in Table 1, as can be seen from Table 1, compared with Normal group, model group mice escape latency obviously shortens (
p< 0.05), errors number obviously reduces (
p< 0.05); Compared with model group, each acteoside administration group all can significant prolongation mice escape latency (
p< 0.01) and minimizing errors number (
p< 0.05 or
p< 0.01).
acteoside surveys the average influence (acteoside: AS) of formula to mice Morris water maze
acteoside is surveyed the average influence of formula to mice Morris water maze and is shown in Table 2, and as can be seen from Table 2, compared with Normal group, model group mice finds platform average latency all prolongation in various degree, from d2 obviously increase later (
p< 0.01); Compared with model group, each acteoside administration group average latency all shortens, after d2 its difference more obviously (
p< 0.05 or
p< 0.01), in addition, compared with blank group, model group wear platform number of times obviously reduce (
p< 0.01); Compared with model group, each acteoside administration group wear the equal showed increased of platform number of times (
p< 0.05 or
p< 0.01).
acteoside is to the average influence of AChE activity in mice serum
acteoside is shown in Table 3 the average influence of AChE activity in mice serum, as can be seen from Table 3, the active significance of model group AChE higher than Normal group (
p< 0.05); The active all significances of each acteoside administration group AChE compared with model group reduce (
p< 0.05 or
p< 0.01).
acteoside is to the average influence of MDA content, SOD vigor and T-ACO ability in mice serum
acteoside is shown in Table 4 the average influence of MDA content, SOD vigor and T-ACO ability in mice serum, as can be seen from Table 4, compared with Normal group, in model group mice serum MDA content obviously increase (
p< 0.01), SOD(
p< 0.05) and T-AOC obviously reduce (
p< 0.05); Compared with model group, each acteoside administration group MDA content all obviously reduces (
p< 0.01), and SOD vigor (
p< 0.05 or
p< 0.01) and T-AOC all significantly raise (
p< 0.01).
acteoside is to the average influence of ChAT vigor in Mice brain tissues
acteoside is shown in Table 5 the average influence of ChAT vigor in Mice brain tissues, as can be seen from Table 5, compared with Normal group, model group Mice brain tissues ChAT activity reduces (
p< 0.01); Compared with model group, the active obviously rising of each acteoside administration group ChAT (
p< 0.05 or
p< 0.01).
acteoside is to the average influence of MDA content, SOD vigor and T-ACO ability in Mice brain tissues
acteoside is shown in Table 6 the average influence of MDA content, SOD vigor and T-ACO ability in Mice brain tissues, as can be seen from Table 6, compared with Normal group, MDA content showed increased in model group Mice brain tissues (
p< 0.01), and SOD vigor and T-AOC all obviously reduce (
p< 0.01); Compared with model group, each acteoside administration group MDA content obviously reduces, and SOD vigor and T-AOC all significantly raise (
p< 0.05 or
p< 0.01).
conclusion
above result shows that acteoside presss from both sides repeatedly to bilateral common carotid arteries and closes the logical learning memory disorder caused again and have certain protective effect.
two. acteoside is on the impact of focal cerebral ischemic in mice Reperfu-sion (MCAO) model
1 experimental technique
1.1 modelings and medication
wistar male rat, body weight 200g to 220g; Experiment divides 5 groups, often organizes 8: (1) sham-operation (blank) matched group; (2) model control group; (3) acteoside low dose group (1mg/kg); (4) dosage group (5mg/kg) in acteoside; (5) acteoside high dose group (25mg/kg); With reference to the method for ZeaLonga etc., Wistar male rat mass percent in model control group and each acteoside low dose group is the chloral hydrate 350mg/Kg intraperitoneal injection of anesthesia of 10%, percent by volume is the ethanol throat skin degerming of 75%, neck median incision, be separated and expose right carotid (CCA) and (ICA), external carotid artery (ECA) in neck, folder closes CCA; Ligation common carotid artery and external carotid artery, be about the ligation of 7mm place apart from common carotid artery crotch, and the fishing line importing the blunt waxdip of head end circle inserts internal carotid artery, with carotid bifuracation place for labelling, advance 18mm to 20mm to feel ligation after resistance, block cerebral blood flow, simultaneously the CCA that closes of open clip; After ischemia 2h, fixing Wistar male rat, pulls out fishing line and realizes Reperfu-sion; Rats in sham-operated group line bolt only inserts 10mm, does not cause cerebral embolism; Wistar male rat body temperature 34 DEG C is maintained, room temperature 28 DEG C before and after modeling; 2 hours gastric infusions after instant after Reperfu-sion and the Reperfu-sion of each acteoside dosage component, Sham-operated control group and model control group identical Reperfu-sion time point after modeling gives isodose normal saline.
neurological deficits score
with reference to 5 grades of point systems that Bederson etc. establishes, the neurologic impairment of the Wistar male rat in sham-operation (blank) matched group after modeling, model control group and each acteoside dosage group is marked: 0 grade: do not observe nervous symptoms; 1 grade: carry tail unsettled time, the operation offside forelimb of Wistar male rat shows as wrist elbow flexing, shoulder inward turning, elbow abduction, is close to thoracic wall; 2 grades: be placed in smooth flat by Wistar male rat, pushing hands art side shoulder moves to offside, and resistance reduces; Roll to operation when 3 grades: Wistar male rat is freely walked or turn-take; 4 grades: Wistar male rat collapses from physical exhaustion, and limbs are without spontaneous activity.
brain stem injury and brain water content measure
after Wistar male rat carries out neurological deficits score, sacrificed by decapitation, the complete brain of rapid taking-up, bloodstain is washed away with the normal saline of pre-cooling, after-20 DEG C of frozen 2h, from bregma, make coronal section totally 5 (2mm), put in 1%TTC solution the 10min that dyes in 37 DEG C of water-baths, lucifuge, computer analysis cerebral infarct size and edema degree.
detect
the brain taken out is extracted total protein, carries out polyacrylamide gel electrophoresis quantitatively, transferring film, closed 2h, primary antibodie 37 DEG C hatches 2h, TBST buffer washes film 3 times, and two resist 37 DEG C hatches 1h, and TBST buffer washes film 3 times, expose, develop a film, scanning, software analysis optical density value.
statistical procedures
experimental result data all represents with mean ± standard deviation, adopts significance between one factor analysis of variance group to compare, compares employing between sample average
tinspection,
p< 0.05 represents that difference has statistical significance.
result
2.1 acteosides are marked to the neurological deficit of brain Focal Cerebral Ischemia Reperfusion Wistar male rat, the average influence of Brain stem injury and cerebral edema
acteoside is marked to the neurological deficit of brain Focal Cerebral Ischemia Reperfusion Wistar male rat, the average influence of Brain stem injury and cerebral edema is shown in Table 7, as can be seen from Table 7, compared with Sham-operated control group, model group Wistar male rat neurological deficit obviously serious (
p< 0.01), Brain stem injury (
p< 0.01) and degree of cerebral edema all obviously increase (
p< 0.01); Compared with model group, each acteoside administration group all can alleviate Wistar male rat neurological deficit (
p< 0.05 or
p< 0.01), and minimizing Brain stem injury (
p< 0.05 or
p< 0.01) and alleviate degree of cerebral edema (
p< 0.05 or
p< 0.01).
the average influence that acteoside is expressed apoptosis-related genes bc1-2, caspase-3
as shown in Figure 2, after ischemia-reperfusion 24h, model group cerebral tissue bc1-2 expression significantly reduces, and caspase-3 expression significantly raises; Each acteoside dosage group significantly can raise bc1-2 expression and reduce caspase-3 expression; Result display acteoside can pass through inhibited apoptosis, and protection ischemical reperfusion injury controls damage and worsens further.
conclusion
acteoside can alleviate neurological deficit, reduces Brain stem injury and alleviates degree of cerebral edema; Thus inhibited apoptosis, the damage that final protection Focal Cerebral Ischemia Reperfusion causes.
three. acteoside intends the average influence of cerebral hypoxia ischemia model to low sugar hypoxia
1 experiment purpose
brain tissue metabolism is vigorous, and blood flow enriches, and therefore brain cell is very responsive to hypoxic-ischemic, causes the infringement of neurocyte function.This experiment is intended to study the impact of acteoside on cell after Hypoxia-hypoglycemia damage, we utilize the oxygen consumption characteristic of sodium dithionite, merge and adopt low sugar DMEM culture medium, cause low sugar hypoxia model, with cerebral cell ischemia anaerobic condition in analogue body, and observe the pharmacodynamic action of acteoside.
experimental technique
2.1 modelings and medication
2.1 modelings and medication
experiment divides 6 groups, often organizes 6 multiple holes: (1) normal group; (2) model group; (3) acteoside 0.001 μm of ol/L; (4) acteoside 0.1 μm of ol/L; (5) acteoside 10 μm of ol/L; (6) acteoside 1000 μm of ol/L; Normal group, after adopting RPMI-1640 and PC12 cell to hatch 2h altogether, discards culture fluid; Other experimental group is with containing 1mmol/LNa
2
s
2
o
4
rPMI-1640 and after PC12 cell hatches 2h altogether, discard culture fluid.(3), the sugar-free RPMI-1640 10 μ L added respectively containing variable concentrations acteoside (0.001 μm of ol/L, 0.1 μm of ol/L, 10 μm of ol/L, 1000 μm of ol/L) is organized in (4) (5) (6), normal group and model group add equal-volume sugar-free RPMI-1640, after continuing to cultivate 24h, detect indices.
acteoside is to the average influence of cell survival rate
after the acteoside adding variable concentrations continues to cultivate 24h, after adding 5mg/mLMTT reaction 4h, suck supernatant, add DMSO, vibrate to be crystallized dissolve completely after survey OD value in 490nm place, calculating cell survival rate, cell survival rate (%)=experimental group/matched group × 100%.
acteoside is to the average influence of lactic acid dehydrogenase in cell (LDH)
after adding variable concentrations acteoside continuation cultivation 24h, suck supernatant, add PBS piping and druming, make suspension, multigelation makes cell breakage, then adopts colorimetry to measure.
acteoside is to the mensuration of cell acetylcholine (Ach) content, acetylcholine transferase (ChAT) and acetylcholinesterase (TChE) vigor
the acteoside adding variable concentrations sucks supernatant after continuing to cultivate 24h, adds PBS piping and druming, make suspension, multigelation makes cell breakage, then adopts alkaline hydroxylamine assay, colorimetry and 5,5-dithio-2-nitrobenzoic acid (DTNB) development process to detect respectively.
acteoside is to the average influence of intraor extracellular MDA content, NO content, SOD vigor, NOS vigor and T-AOC vigor
the acteoside adding variable concentrations sucks supernatant after continuing to cultivate 24h, and add PBS piping and druming, make suspension, multigelation makes cell breakage, then adopts Nanjing to build up institute test kit and detects.
statistical procedures
experimental result data all represents with mean ± standard deviation, adopts significance between one factor analysis of variance group to compare, compares employing between sample average
tinspection,
p< 0.05 represents that difference has statistical significance.
result
3.1 acteosides are to the average influence of low sugar hypoxia injury PC12 cell survival rate and cell membrane integrity
the average influence of acteoside to low sugar hypoxia injury PC12 cell survival rate and cell membrane integrity is shown in Table 8; as can be seen from Table 8; acteoside can improve the damage that Hypoxia-hypoglycemia causes PC12 cell; improve cell survival rate; reduce LDH in cell and spill rate, the integrity of Cell protection film.
acteoside is to the average influence of low sugar hypoxia injury PC12 cell Ach content
acteoside to the average influence of low sugar hypoxia injury PC12 cell Ach content in table 9, as can be seen from Table 9,1mmol/LNa
2
s
2
o
4
can cause PC12 cell Ach content reduce (
p< 0.01); With variable concentrations acteoside hatch altogether rear all can significantly improve Ach content (
p< 0.01).
acteoside is to the average influence of low sugar hypoxia injury PC12 cell ChAT vigor, TChE and ChAT/TChE ratio
the average influence of acteoside to low sugar hypoxia injury PC12 cell ChAT vigor, TChE and ChAT/TChE ratio is shown in Table 10, as can be seen from Table 10, and the Na of 1mmol/L
2
s
2
o
4
can cause PC12 cell ChAT vigor and ChAT/TChE ratio all reduce (
p< 0.01,
p< 0.05); After hatching altogether with variable concentrations acteoside, variable concentrations acteoside all can significantly improve ChAT vigor and ChAT/TChE ratio (
p< 0.01), but TChE vigor is had no significant effect.
acteoside is to the average influence of low sugar hypoxia injury PC12 cell MDA content, SOD vigor and T-AOC ability
experimental result shows, the average influence of acteoside to low sugar hypoxia injury PC12 cell MDA content, SOD vigor and T-AOC ability is shown in Table 11, as can be seen from Table 11, and 1mmol/LNa
2
s
2
o
4
pC12 cell MDA content can be caused to raise, SOD vigor (
p< 0.01) and the reduction of T-AOC ability (
p< 0.01); After hatching altogether with variable concentrations acteoside, variable concentrations acteoside all can obviously reduce MDA content (
p< 0.01) and increase SOD vigor (
p< 0.01) and T-AOC ability (
p< 0.01,
p< 0.05).
acteoside is on the impact of low sugar hypoxia injury PC12 cell NO content and NOS vigor
the average influence of acteoside to low sugar hypoxia injury PC12 cell NO content and NOS vigor is shown in Table 12, as can be seen from Table 12, and 1mmol/LNa
2
s
2
o
4
pC12 cell NO content can be caused to raise, NOS vigor reduces (
p< 0.01); After hatching altogether with variable concentrations acteoside, variable concentrations acteoside all can obviously reduce NO content (
p< 0.01) and increase NOS vigor (
p< 0.01).
conclusion
above result shows that acteoside causes cell hypoxic-ischemic to have certain protection and therapeutical effect to Hypoxia-hypoglycemia.
in sum, acteoside repeatedly presss from both sides bilateral common carotid arteries and closes the logical learning memory disorder caused again and have certain protective effect; Can neurological deficit be alleviated, reduce Brain stem injury and alleviate degree of cerebral edema; Thus inhibited apoptosis, the damage that final protection Focal Cerebral Ischemia Reperfusion causes; Acteoside causes cell hypoxic-ischemic to have certain protection and therapeutical effect to Hypoxia-hypoglycemia simultaneously.
above technical characteristic constitutes embodiments of the invention, and it has stronger adaptability and implementation result, can increase and decrease non-essential technical characteristic according to actual needs, meet the demand of different situations.
Claims (3)
1. the application of acteoside in preparation treatment of vascular anti-dementia agent.
2. the application of acteoside according to claim 1 in preparation treatment of vascular anti-dementia agent, is characterized in that the dosage form of acteoside is the one in tablet, pill, granule, capsule, suspension, solution, syrup, injection, cream, ointment, gel, spray, chewing agent and patch.
3. the application of acteoside according to claim 1 in preparation treatment of vascular anti-dementia agent, is characterized in that: acteoside is with dry product weighing scale, and the mass percentage of acteoside is 41% to 99.9%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410076061.6A CN103816169B (en) | 2014-03-03 | 2014-03-03 | The application of acteoside in preparation treatment of vascular anti-dementia agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410076061.6A CN103816169B (en) | 2014-03-03 | 2014-03-03 | The application of acteoside in preparation treatment of vascular anti-dementia agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103816169A CN103816169A (en) | 2014-05-28 |
| CN103816169B true CN103816169B (en) | 2016-01-06 |
Family
ID=50751654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410076061.6A Active CN103816169B (en) | 2014-03-03 | 2014-03-03 | The application of acteoside in preparation treatment of vascular anti-dementia agent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103816169B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106581019B (en) * | 2016-12-13 | 2019-11-01 | 新疆维吾尔自治区维吾尔医药研究所 | Acteoside is preparing the purposes in anxiolytic drugs |
| CN112915095A (en) | 2019-12-06 | 2021-06-08 | 罗胥恩 | Chronic wound healing composition and application thereof |
| CN115607557A (en) * | 2021-07-16 | 2023-01-17 | 上海医药工业研究院 | Application of compound as plasma kallikrein inhibitor |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1526400A (en) * | 2003-03-04 | 2004-09-08 | 杭州天力药业有限公司 | Tubiflorous desert cistanche prepn containing phenethyl alcohol glycoside and its prepn process and use |
| CN102499322A (en) * | 2009-09-30 | 2012-06-20 | 杏辉天力（杭州）药业有限公司 | Novel health-care food or drug with function of improving memory |
-
2014
- 2014-03-03 CN CN201410076061.6A patent/CN103816169B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1526400A (en) * | 2003-03-04 | 2004-09-08 | 杭州天力药业有限公司 | Tubiflorous desert cistanche prepn containing phenethyl alcohol glycoside and its prepn process and use |
| CN102499322A (en) * | 2009-09-30 | 2012-06-20 | 杏辉天力（杭州）药业有限公司 | Novel health-care food or drug with function of improving memory |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103816169A (en) | 2014-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103816169B (en) | The application of acteoside in preparation treatment of vascular anti-dementia agent | |
| CN103751722B (en) | The preparation method of the Chinese medicine oral liquid for the treatment of infantile spasm disease | |
| CN109265514B (en) | Memory improving peptide for resisting gastrointestinal tract digestion and application thereof | |
| Cendelín et al. | The effect of repeated rotarod training on motor skills and spatial learning ability in Lurcher mutant mice | |
| CN101961345B (en) | Medicinal composition having anti-fatigue function | |
| CN108851089A (en) | Alleviate the tablet and its preparation process of physical fatigue | |
| US20160129025A1 (en) | Anti-fatigue composition and use thereof | |
| CN102786414A (en) | Compound for treating and/or preventing neurodegenerative related disease | |
| CN105646611B (en) | Two caffeoyl spermidine derivatives glucosides of one kind and application thereof | |
| CN102716142A (en) | Application of icariin to preparation of medicine for treating parkinsonism | |
| CN1316976C (en) | Use of kaempferol-3-O-glubulariacitrin in preparing medicine for senile dementia | |
| CN102727499A (en) | Application of compound 6-furfurylaminopurine in preparations of anti-vascular dementia drugs | |
| CN101658522B (en) | Application of tacrine short-chain dimer in preparation of medicament for treating neurodegenerative diseases | |
| CN103232350A (en) | Acylated Danshensu derivative and application thereof to preventing and treating cerebrovascular and liver and kidney diseases | |
| Takubo et al. | Effects of hop extracts on nasal rubbing and sneezing in BALB/c mice | |
| CN104324357B (en) | The application of sika deer deer spleen extract in anti-fatigue medicament | |
| CN103222983A (en) | Use of peracetylated chitooligosaccharide in preparing drug for treating neurodegenerative disease | |
| CN111214476A (en) | Medicine composition for preventing and treating senile dementia | |
| RU2484814C1 (en) | Pharamceutical composition for treatment of oncological diseases | |
| CN102895602B (en) | Chinese medicinal preparation for preventing and treating depression | |
| Zakir et al. | Caffeine (1, 3, 7-trimethylxanthine): The good and the bad: A review | |
| CN105213356A (en) | The application of hydroxytyrosol in the medicine of the anti-angiogenic property dementia of preparation | |
| Sy et al. | Myorelaxant and antispasmodic effects of the aqueous extract of Mitragyna inermis barks on Wistar rat ileum | |
| WO2019114676A1 (en) | New medical use of persimmon leaf extract and of preparation of persimmon leaf extract | |
| CN104510752A (en) | Medical application of astrapterocarpan |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Yan Ming Inventor after: Gao Li Inventor after: Huo Shixia Inventor after: Peng Xiaoming Inventor after: Li Jianmei Inventor before: Yan Ming Inventor before: Gao Li Inventor before: Huo Shixia Inventor before: Peng Xiaoming |
|
| COR | Change of bibliographic data | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |